Application of novel clinicopathological biomarkers to cancer treatment

在唾液腺癌中，RB1CC1被证明是一个有用的预后预测因子。在头颈癌中，QL1和WRN DNA解旋酶是治疗的靶标分子，siRNA沉默可特异性导致肿瘤细胞死亡。p62/SQSTM1在头颈癌中高表达。p62/SQSTM1可诱导GSH，引起氧化应激抵抗，与放射治疗抵抗相关，最终预测较差的预后。在睾丸胚胎癌中，SOX2-siRNA在体内对肿瘤生长有明显的抑制作用，这表明它将是一个有前景的治疗靶点。

In salivary gland cancers, RB1CC1 was demonstrated to be a useful prognostic predictor. In head and neck carcinomas, QL1 & WRN DNA helicase were therapeutic targetting molecules, and the siRNA silencing could result specifically cell death in the cancers. p62/SQSTM1 was highly expressed in head and neck carcinomas. p62/SQSTM1 could induce GSH, cause a resistance to oxidative stress, be associated with a resisitance to radiation therapy, and finally predict the worse prognosis. In testicular embryonal carcinomas, SOX2-siRNA caused significant inhibition for the tumor growth in vivo, suggesting that it will be a promising therapeutic target in the future.